|Bid||2,550.00 x 0|
|Ask||2,550.00 x 0|
|Day's range||2,546.00 - 2,601.00|
|52-week range||1,596.00 - 2,768.00|
|Beta (5Y monthly)||0.05|
|PE ratio (TTM)||12.07|
|Earnings date||25 Feb 2021 - 01 Mar 2021|
|Forward dividend & yield||0.24 (0.94%)|
|Ex-dividend date||20 Aug 2020|
|1y target est||23.92|
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Hikma Pharmaceuticals, a multi-national pharmaceutical company and leading licensing partner in the Middle East and North Africa ("MENA") region specializing in the development and commercialization of a broad range of high-quality medicines, today announced that the companies have entered into an exclusive licensing agreement for the registration and commercialization of Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer ("NMIBC") and other types of cancer in MENA. Vicineum, a locally administered fusion protein, is Sesen Bio’s lead product candidate currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive NMIBC. In December 2019, the Company initiated the BLA submission for Vicineum to the FDA under Rolling Review.
After Amarin lost its patent rights in the U.S., the stock crashed overnight. Investors might want to stay optimistic.
MGE Energy's (NASDAQ:MGEE) stock is up by 7.8% over the past three months. Given that the stock prices usually follow...